Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model Avio-Maria Perna * , Emanuela Masini † , Silvia Nistri ‡ , Vittorio Briganti § , Laura Chiappini ‡ , Pierluigi Stefano * , Mario Bigazzi || , Cesco Pieroni § , Tatiana Bani Sacchi ‡ and Daniele Bani ‡ ,1 * Unit of Cardiac and Experimental Surgery, Careggi Hospital, Florence; † Department of Preclinical and Clinical Pharmacology, University of Florence, Italy; ‡ Department of Anatomy, Histology and Forensic Medicine, University of Florence, Italy; § Unit of Nuclear Medicine, Careggi Hospital, Florence Italy; and || Prosperius Institute, Florence, Italy 1 Correspondence: University of Florence, Dept. Anatomy, Histology and Forensic Medicine, Viale G. Pieraccini, 6. I-50139 Florence, Italy. E-mail: daniele.bani@unifi.it <h3>SPECIFIC AIMS</h3> Relaxin, best known for its effects on reproduction, has recently been validated as a cardiotropic hormone, being produced by the heart and acting on specific heart receptors. Our previous studies in rodents subjected to cardiac ischemia/reperfusion have shown that relaxin, given preventatively before ischemia, reduces myocardial injury and increases survival of the infarcted animals. From the clinicians’ viewpoint, these studies raise the intriguing question as to whether relaxin is also able to
/lp/fed-of-american-socs-for-experimental-biology/novel-drug-development-opportunity-for-relaxin-in-acute-myocardial-Geu0is0Q8o